<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882436</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC2020CR010-001</org_study_id>
    <nct_id>NCT04882436</nct_id>
  </id_info>
  <brief_title>Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia</brief_title>
  <official_title>Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence rate and mortality of lung infection are high worldwide. It is a common and&#xD;
      frequently occurring disease which seriously threatens human health. Severe pneumonia&#xD;
      accounts for 18-36% of all pneumonia. Severe pneumonia has caused serious economic and&#xD;
      medical burden. Therefore, it is urgent to carry out the real-world cohort study of severe&#xD;
      pneumonia. Big data and sample library will provide useful clinical guidance and scientific&#xD;
      research reserves for clinicians. Through further research, we can improve the treatment&#xD;
      success rate and reduce the mortality.&#xD;
&#xD;
      The purpose of this study is to provide reliable biological samples and related data&#xD;
      information for the relevant basic and clinical trials in the field of severe pneumonia by&#xD;
      carrying out the construction of special disease cohort database and biological sample&#xD;
      holographic database, and to establish a long-term sharing platform for the transformation of&#xD;
      research results into clinical practice, improve the prognosis of severe pneumonia,and&#xD;
      provide the evidence for improving the diagnosis and treatment of severe pneumonia suitable&#xD;
      for China's national conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>180 Days</target_duration>
  <primary_outcome>
    <measure>clinical outcome of patients with severe pneumonia</measure>
    <time_frame>day 3, day 7, day 14, day 30, day 180.</time_frame>
    <description>The pneumonia is cured or improved, or the treatment of pneumonia is invalid, or the patient is dead.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Severe Pneumonia</condition>
  <condition>Special Disease Cohort Database</condition>
  <condition>Holographic Library of Biological Samples</condition>
  <arm_group>
    <arm_group_label>severe pneumonia</arm_group_label>
    <description>Patients with severe pneumonia</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      intravenous blood, sputum, urine, bronchoalveolar lavage fluid and pleural effusion&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of severe pneumonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recent cough, expectoration or aggravation of original respiratory diseases, with or&#xD;
             without purulent sputum / chest pain / dyspnea / hemoptysis&#xD;
&#xD;
          -  Fever&#xD;
&#xD;
          -  Signs of pulmonary consolidation and / or moist rales&#xD;
&#xD;
          -  Peripheral blood leukocytes &gt;10×10^9/L or less than 4×10^9/L, with or without nucleus&#xD;
             shifting to the left.&#xD;
&#xD;
          -  New patchy infiltration, consolidation of lobes / segments, ground glass opacity or&#xD;
             interstitial changes, with or without pleural effusion on chest imagings&#xD;
&#xD;
          -  Positive etiological examination&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Need mechanical ventilation; septic shock need vasoactive drug treatment. Meet one of&#xD;
             them.&#xD;
&#xD;
          -  ① respiratory rate ≥ 30 beats / min; ② oxygenation index (PaO2 / FiO2) ≤ 250; ③&#xD;
             multilobar infiltration; ④ disturbance of consciousness / disorientation; ⑤ azotemia&#xD;
             (BUN ≥ 20mg / dl); ⑥ cytopenia (WBC &lt; 4.0 × 109 / L); ⑦ thrombocytopenia (platelet &lt;&#xD;
             10.0 × 109 / L); Ⅷ low body temperature (T &lt; 36 ℃); Ⅸ hypotension, requiring strong&#xD;
             fluid resuscitation. Meet the above three requirements at the same time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ● Cannot understand and / or implement the investigation protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieming Qu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieming Qu, MD,PhD</last_name>
    <phone>+86-21-64370045</phone>
    <email>jmqu0906@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Medical School of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieming Qu, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <email>jmqu0906@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

